Alnylam Submits CTA Application For ALN-APP, An Investigational RNAi Therapeutic For The Treatment…
- Company Expects to Initiate a Phase 1 Study in Early-Onset Alzheimer’s Disease in Early 2022, with Initial Human Data at or Around Year-End 2022 -…